Eli Lillys experimental Alzheimers drug slows cognitive decline by 35%
New York, May 4: US pharma giant Eli Lilly's experimental Alzheimer's drug slowed clinical decline by 35 per cent compared to placebo, and resulted in 40 per cent less decline on the ability to perform activities of daily living, said the company announcing phase-3 trial results.